Ziopharm Oncology Inc. announced positive data updates supporting survival benefit and the underlying immune system mechanism for Ad-RTS-hIL-12 plus veledimex, the company’s controlled human interleukin-12 gene therapy candidate for brain cancer, at the 22nd Annual Meeting and Education Day of the Society for Neuro-Oncology.
Alexandra Miller, a neurologist and neuro-oncologist specializing in treating primary brain tumors, has been named as the chief of the Division of Neuro-Oncology and co-director of the Brain and Spine Tumor Center at NYU Langone Health’s Perlmutter Cancer Center, effective Jan. 29.
